Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

Fig. 4

IHC staining and quantification of tau pathology. Three bregma-matched brain sections from each PS19 mice receiving vehicle (n = 12), or 3 mg/kg (n = 11) or 10 mg/kg (n = 12) of 51657, were stained with AT8 antibody to visualize tau pathology. a Representative images from a vehicle-treated PS19 mouse with an average amount of tau pathology (Bregma − 2.5). Regions of stained sections encompassing the hippocampus and entorhinal cortex were imaged and a fixed threshold was applied to distinguish AT8-positive staining from background (images on right; yellow, low AT8 signal; orange, moderate AT8 signal; red, high AT8 signal), followed by quantification of AT8-positive tau pathology. b A plot of the combined AT8-positive pathology from the entorhinal cortex and hippocampus from PS19 mice in each treatment group reveals a trend toward reduced tau pathology in the 51657-treated mice

Back to article page